Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study.
J Neurol
; 267(10): 2851-2864, 2020 Oct.
Article
in En
| MEDLINE
| ID: mdl-32451615
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Multiple Sclerosis, Relapsing-Remitting
/
Daclizumab
/
Immunosuppressive Agents
/
Multiple Sclerosis
Type of study:
Clinical_trials
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
En
Journal:
J Neurol
Year:
2020
Document type:
Article
Affiliation country:
Country of publication: